Olema Pharmaceuticals has announced the presentation of initial clinical data from its Phase 1 study of OP-3136, a novel oral selective KAT6A/B inhibitor, at the upcoming ASCO Annual Meeting. This first-in-human study evaluates OP-3136 as a monotherapy in advanced solid tumors and in combination with endocrine therapy for ER+, HER2− advanced breast cancer. The poster presentation is scheduled for May 30, 2026, and will showcase preliminary results that could inform future clinical applications.

The significance of OP-3136 lies in its targeted mechanism against lysine acetyltransferase 6 (KAT6), an epigenetic regulator implicated in various cancers, including breast cancer. Preclinical studies have demonstrated that OP-3136 exhibits substantial anti-proliferative activity in ER+ breast cancer models and shows potential for synergistic effects when combined with existing therapies like palazestrant and CDK4/6 inhibitors. This positions OP-3136 as a promising candidate to enhance treatment efficacy in patients who have become resistant to current endocrine therapies.

The implications of this research extend to the broader landscape of breast cancer treatment paradigms. The development of OP-3136 could shift the focus toward epigenetic targets in cancer therapy, potentially accelerating the timeline for integrating such inhibitors into clinical practice. As Olema continues to advance its pipeline, including the pivotal Phase 3 trials for palazestrant, the outcomes of OP-3136 may inform future drug development strategies, particularly in addressing resistance mechanisms in endocrine-driven cancers.

Source: globenewswire.com